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Background: The number of unintentionally childless couples is increasing as more couples seek to conceive for
the first time in the third or fourth decade of the woman’s life. Determination of ovarian reserve is an essential
component of infertility assessment. The Anti-Müllerian-Hormone (AMH) seems to be the most reliable predictor of
ovarian reserve. In this study we analyzed AMH in a cohort of pregnant women without fertility impairment to
determine age-dependent decline and possible AMH fluctuations during pregnancy and postpartum.
Methods: A total of 554 healthy women aged 16 to 47 years without history of infertility or previous surgery on
the ovaries were enrolled in the study between 1995 and 2012. In 450 women, a single measurement of AMH was
taken during pregnancy, allowing for cross sectional analysis of trimester- and age-related differences in AMH levels.
For another 15 women longitudinal data on AMH levels for all trimesters was recorded. In addition, for 69 women
AMH was measured at the time just before and after delivery, and for another 20 AMH was measured just before
delivery and once on each of the first four days after delivery. We used AMH-Gen-II ELISA (Beckman Coulter,
Immunotech, Webster, USA) for the assessment of AMH levels. Non-parametric statistical tests were used to
compare AMH levels between age groups, trimesters and postpartum.
Results: Comparison between the trimesters revealed a significant difference in AMH values at each trimester
(first trimester: 1.69 ng/ml (IQR 0.71–3.10), second trimester: 0.8 ng/ml (IQR 0.48–1.41), third trimester: 0.5 ng/ml
(IQR 0.18–1.00)). AMH significantly dropped during the course of pregnancy and immediately after delivery, whereas
an increase was observed over the first four days postpartum. Women, greater than or equal to 35 years, showed
significant lower AMH levels than those <35 years across all trimesters.
Conclusions: AMH levels decrease during pregnancy. The decline in AMH levels during pregnancy indicates
ovarian suppression. AMH levels recover quickly after delivery. AMH levels assessed in pregnant women are not an
accurate indicator of ovarian reserve, since AMH levels during pregnancy seem not to be independent of
gestational age.
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There has been an increase in the number of uninten-
tionally childless couples with the increase in the average
age of first conception. One explanation for this might
be a significantly reduced ovarian reserve in older
women. It is well known that the ovarian reserve steadily
decreases from the onset of puberty until menopause
[1]. Iatrogenic reduction of ovarian reserve may be* Correspondence: angela.koeninger@uk-essen.de.
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reproduction in any medium, provided the orcaused by surgeries to remove endometriosis and cysts;
these procedures are more frequently performed in to-
day’s era of minimally invasive surgery [2]. In addition,
genetic disorders may also play a role in early loss of
ovarian reserve [3].
There are various known parameters for assessing
ovarian reserve, including ovarian volume, antral follicle
count, follicle stimulating hormone (FSH) and Inhibin B
at the beginning of the menstrual cycle, as well as Anti-
Müllerian-Hormone (AMH) [4,5]. AMH is produced by
the granulosa cells of small antral and prae-antralal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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size of the pool of these follicles in animal models as
well as in the human ovary [6-8]. Furthermore, AMH in-
hibits the initiation of follicle growth and the FSH-
dependent selection process [9-11]. AMH correlates very
well with the sonographically measurable antral follicle
count and has been shown to decrease with increasing
age [12]. AMH is currently considered to be the most
reliable predictor of the ovarian reserve [7,12,13]. By
contrast to established factors like age, FSH, estradiol
and Inhibin B, AMH reflected the pool of primary and
secondary follicles and indicates the age-dependent de-
cline of the follicle pool before other factors change [13].
The number of oocytes retrieved in IVF protocols
strongly correlated with the ovarian reserve. AMH pre-
dicted more precisely the quantity of oocyte retrieval
than other factors [14]. AMH levels seemed not to vary
during the menstrual cycle [15-17]. No changes in AMH
levels over the course of pregnancy had heretofore been
reported [18]. In addition, the intake of hormonal sub-
stances had up to now been believed to have no signifi-
cant effect on AMH levels [19].
Most recent studies investigating AMH levels before
pregnancy were conducted in populations of women re-
ceiving in-vitro fertilization. Gnoth et al. [14] demon-
strated that the level of AMH before ovarian stimulation
correlated with the number of punctured oocytes, which
led to the acceptance of low AMH levels as a predictor
of poor ovarian response. Clinical pregnancy rates, how-
ever, showed no correlation with AMH levels. Our clinical
experience is consistent with this finding, showing that
some women with very low or even undetectable AMH
levels get pregnant naturally and give birth at full term.
Since recent research has argued that AMH levels de-
cline only with respect to age and not because of hormo-
nal changes (e.g. contraception), we sought to examine
AMH levels to determine the age-dependent decline in a
cohort of pregnant women without fertility impairment.
The further aim was to evaluate possible AMH fluctua-
tions during the course of pregnancy and postpartum.
We therefore sought to investigate the reliability of
AMH as a marker of ovarian reserve in a highly
hypogonadotropic state such as pregnancy.
Methods
Study population
554 healthy women aged 16 to 47 years (mean±SD: 30.8
± 6.2 years) without history of infertility or previous
surgery on the ovaries were enrolled in the study. All
patients were treated in the clinic for obstetrics and
gynaecology at the University Hospital of Essen,
Germany, between 1995 and 2012. All of them con-
ceived naturally without artificial infertility treatment.
None of the patients had a history of chemotherapy orradiation treatment. Women with a history of ovarian
surgery were excluded from the study.
Patients were enrolled in the study in order as they
appeared in the clinic. Informed written consent was
obtained from all women, and the study was approved
by the local research ethics committee (number 11–
4643). The Helsinki Declaration was followed through-
out the study.
Study design
AMH levels during pregnancy
AMH was studied prospectively in the third trimester
(≥ 29th week of gestation) in 339 women presenting in
our clinic between 2011 and 2012. Since AMH levels
were very low, we retrospectively studied serum samples
taken during the first (n=58; ≤ 14th week of gestation)
and second (n=53; 15–28 weeks of gestation) trimester
from women seen in our clinic between 2007 and 2011.
AMH levels were analyzed separately for each trimester
according to age groups (≤27 years, 28–34 years and ≥35
years). Sample size was adequate to detect even small
differences in AMH levels between trimesters as previ-
ously suggested [18].
In addition, to determine the relevance of AMH levels
longitudinally during the course of pregnancy, 15 pa-
tients with blood samples from each trimester, present-
ing in our clinic between 1995 and 2001, were evaluated
for AMH levels retrospectively.
AMH levels peripartal
69 women were studied prospectively between 2011 and
2012 by taking one blood sample during admission for
delivery and one additional blood sample within the first
four days after delivery. Another 20 patients had blood
samples taken at the time just before delivery and add-
itionally during each of the first four days after delivery
to assess AMH levels during this period.
Sampling of serum
Blood samples (9 ml) were collected from each woman
using S-Monovettes (Sarstedt AG & Co.), stored at 4°C
and processed within 4 hours to avoid blood cell lysis.
Blood fractionation was carried out by centrifugation for
10 minutes at 2500xg. Subsequently, 3 to 4 ml of the
upper phase, constituting blood serum, were removed
for the assessment of AMH levels.
Determination of AMH levels
For AMH determination, we used serum samples in
which the enzymatically amplified two-site AMH-Gen-II
ELISA was applied (Beckman Coulter, Immunotech,
Webster, Texas, USA). Briefly, undiluted serum samples
and controls were dispensed into the wells coated with
anti-AMH antibody, followed by the addition the anti-
Figure 1 Boxplots illustrating the distribution of AMH levels for
each trimester including all age groups.
Figure 2 Boxplots illustrating the distribution of AMH levels for
each trimester including women aged ≤27 years.
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washing, 100 μl of the streptavidin-horseradish peroxid-
ase (HRP) was added, followed by the addition of 100 μl
substrate solution containing TMB for 8–12 minutes.
The degree of enzymatic turnover of the substrate was
determined by dual wavelength absorbance measure-
ment at 450 nm and between 600 and 630 nm using an
automatic ELISA reader (Bio-Rad, Hercules, CA). The
absorbance measured was directly proportional to the
concentration of AMH in the samples which was calcu-
lated from the calibration curve. The results were
expressed in ng/ml according to the established standard
curve. Concentrations below 0.08 ng/ml were considered
undetectable.
Statistical analysis
As AHM levels were found not to be normally distrib-
uted in the study population, results are reported as me-
dian and interquartile ranges (IQR). The Kruskal-Wallis
test with post hoc Wilcoxon rank-sum test was used to
analyze differences in AMH levels between trimesters
and age groups. Differences between pre- and postpar-
tum AMH levels were analyzed using the Wilcoxon
signed rank test. For the analysis of differences between
AMH levels assessed before delivery and at the first four
days postpartum, as well as for analyzing trends pro-
spectively during trimesters, Friedman rang sum test
with post hoc Wilcoxon-Nemenyi-McDonald-Thompson
test was used.
The level of statistical significance was set at α = 0.05.
For post hoc multiple testing we adjusted the alpha-level
using Bonferroni’s method (αBF~0.017 for comparing tri-
mesters and αBF~0.005 for comparing AHM levels be-
fore delivery and the first four days postpartum).
All analyses were performed using the R statistical
package version 2.15.2 and SAS 9.2 (SAS Institute, Cary
NC) [20].
Results
AMH levels during pregnancy stratified by trimesters
The comparisons between the trimesters in the 450 pa-
tients with single AMH measurements revealed signifi-
cant differences in AMH median values between each
trimester. AMH dropped significantly from the first to
the second trimester [1.69 ng/ml (IQR 0.71 - 3.10) ver-
sus 0.80 ng/ml (IQR 0.48 - 1.41); p < 0.001] and from
the second to the third trimester [0.80 ng/ml (IQR 0.48-
1.41) versus 0.50 ng/ml (IQR 0.18 - 1.00); p < 0.01]
(Figure 1). When this sample was analyzed stratified by
age groups, the following results were obtained: In the
age group of ≤27 years (group 1), there was a significant
difference between the median values obtained for the
first and third trimester as well as for the second and
third trimester (p < 0.001) (Figure 2). In the 28–34 yearage group (group 2), differences in AMH levels turned
out to be significant between each trimester, with de-
creasing median values from first to second trimester
(p < 0.01) and from second to third trimester (p=0.016)
(Figure 3). In the ≥35 years age group (group 3) there
were no significant differences in AMH median values
observed between all trimesters (p > 0.05) (Figure 4). An
overview of AMH median values and the respective IQR
for patients with single AMH measurements stratified
by age group and trimester is given in table 1.
Figure 3 Boxplots illustrating the distribution of AMH levels for each trimester including women aged 28–34 years.
Figure 4 Boxplots illustrating the distribution of AMH levels for each trimester including women aged ≥ 35 years.
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Table 1 AMH median values and interquartile ranges (IQR) stratified by age group and trimester (n=450)
Age First trimester Second trimester Third trimester
≤27 years 2.12 ng/ml (IQR 1.06–3.57) 1.70 ng/ml (IQR 1.00–2.18) 0.72 ng/ml (IQR 0.35–1.08)
28–34 years 1.93 ng/ml (IQR 1.06–2.70) 0.98 ng/ml (IQR 0.71–1.27) 0.49 ng/ml (IQR 0.26–1.14)
≥ 35 years 0.61 ng/ml (IQR 0.37–1.01) 0.26 ng/ml (IQR 0.08–0.62) 0.20 ng/ml (IQR 0.07–0.55)
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In 15 patients AMH levels were measured in multiple
blood samples during the entire course of pregnancy.
Figure 5 shows that the overall trend of AMH levels dur-
ing the course of pregnancy is inversely related to gesta-
tional age. Using the first measured value per patient in
each trimester for analysis, statistically significant differ-
ences were observed between the first and the third
[2.73 ng/ml (IQR 1.87 - 3.25) versus 1.38 ng/ml (IQR
1.03 - 1.72); p < 0.0001] as well as between the second
and the third trimester [2.36 ng/ml (IQR 1.59 - 2.95)
versus 1.38 ng/ml (IQR 1.03 - 1.72); p < 0.01].
AMH levels during pregnancy stratified by age
In the 450 patients with single AMH measurements,
analyses stratified by age revealed that the AMH levels
in age groups 1 and 2 did not differ significantly across
all trimesters. In contrast, age group 3 showed a signifi-
cantly lower AMH median value compared to group 1
(p < 0.01 in the first trimester; p < 0.001 in the second
trimester; p < 0.0001 in the third trimester) as well as
compared to group 2 (p < 0.01 in the first trimester;
p < 0.001 in the second trimester; p < 0.0001 in the third
trimester) (Table 1).Figure 5 Trends of AMH levels during the course of pregnancy in woAMH levels pre- and postpartal
In the 69 patients, for whom the AMH levels were de-
termined immediately before delivery and during the
first four days postpartum, there was a significant differ-
ence between pre- and postpartal median values, show-
ing that AMH levels continue decreasing shortly after
delivery [0.57 ng/ml (IQR 0.18–1.15) versus 0.42 ng/ml
(IQR 0.14–0.90); (p < 0.0001)] (Figure 6).
In the 20 patients for whom AMH levels were deter-
mined before delivery and at each of the first four days
postpartum there was a statistically significant increase
of AMH median values only between day one and day
four [0.20 ng/ml (IQR 0.04–0.56) versus 0.36 ng/ml
(IQR 0.15–0.58); p<0.005] (Figure 7).
Discussion
Although AMH has been considered to be a surrogate
marker of ovarian reserve, up to now only a few studies
have examined the role of AMH in pregnancy and post-
partum. Here we studied AMH in a population of 554
pregnant women without fertility impairment to explore
age-dependent AMH levels and changes in AMH during
the course of pregnancy and postpartum. AMH levels
during pregnancy seem to be inversely related to age.men with multiple AMH measurements (n=15).
Figure 6 Boxplots illustrating the distribution of AMH levels in
women with AMH measurements prepartum and postpartum
(n=69).
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crease with increasing gestational age in a cross sectional
study population as well as longitudinally. Furthermore,
AMH levels seem to drop postpartum compared to levels
measured shortly before delivery, but there is some evi-
dence that AMH levels increase again during the first
four days postpartal.Figure 7 Boxplots illustrating the distribution of AMH levels in wome
four days postpartum (n=20).Unexpectedly low AMH
We first examined AMH levels in women who gave
birth after a full term pregnancy. We observed unexpect-
edly low AMH levels in the study sample. In women
younger than 28 years, the median value determined in
the third trimester was 0.72 ng/ml and the median value
of all age groups was 0.5 ng/ml.
Kelsey et al.[1] described an age-related standard curve
of AMH over a lifetime based on a variety of studies.
The authors found a peak at 25.4 years at an average of
4 ng/ml. According to studies by Gnoth et al. [14], the
threshold between normal and poor response of ovarian
stimulation in a cohort receiving in-vitro- fertilization
was 1.26 ng/ml. In comparison with the infertile cohort
of Gnoth et al. [14] and the standard curve determined
by Kelsey et al. [1], the median value of 0.50 ng/ml in
the third trimester observed in our study seemed to be
unexpectedly low, suggesting that AMH levels during
pregnancy do not represent a reliable predictor of ovar-
ian reserve.AMH decline
Since AMH levels found at the end of pregnancy were
unexpectedly low, we compared AMH levels in different
trimesters. In this context, we demonstrated that AMH
levels decreased significantly with increasing gestational
age. We confirmed these results longitudinally in a co-
hort, measuring AMH levels at each trimester in womenn with AMH measurements prepartum and at each of the first
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week during pregnancy. A comparable study with differ-
ent results was published by La Marca et al. [18] who
determined AMH in every trimester of pregnancy as
well as in a small cohort of non-pregnant women in a
cross sectional analysis (control group: n=15, group with
AMH measurements in the first trimester: n=27, group
examined in the second trimester: n=21, group with
AMH measurements in the third trimester: n=13,
postpartal group: n=8). La Marca et al. saw a trend to-
wards lower AMH levels in the third trimester without
statistical significance [18].
The diverging results observed by La Marca et al. [18]
may reflect their relatively small study population (n=76,
i.e. controls and pregnant women) that was not well
powered to detect small differences in AMH levels be-
tween trimesters. By contrast, we examined 450 preg-
nant women in cross-sectional analysis. In addition to
the cross-sectional examination, we were able to confirm
our results longitudinally in a cohort of 15 patients with
measurements in each of the trimesters. To our know-
ledge, this is the first study showing an AMH decline
during pregnancy including longitudinal data.
Age dependence
Analyzing AMH levels according to age showed that
AMH levels in all trimesters did not differ significantly
in the two age groups below 35 years, whereas women
aged ≥ 35 years had significantly lower AMH levels. In
contrast, the course of AMH drop was different within
every age group. In women aged ≤ 34 years, a significant
decrease of AMH between different trimesters was ob-
served. In older women aged ≥35 years only non-
significant differences between the different trimesters
were obtained which might be due to the overall low
ovarian reserve of the older patients. With regard to the
cross sectional analyses across all age groups, a decrease
in AMH median values of approximately 50% could be
observed in subsequent trimesters.
Pre- and postpartum
In a subset of women, we were able to compare AMH
levels pre- and postpartal, finding a significant drop of
AMH after delivery. Furthermore, a more detailed ana-
lysis of AMH levels within the first four days postpartal
suggests that a further decrease of AMH one day post-
partum is followed by a significant increase up to day
four postpartum.
La Marca et al. [18] also explored postpartal AMH
levels, but in a cross sectional design. The authors did
not observe differences between postpartal, i.e. two or
three days after delivery, and AMH levels in pregnancy.
The differing study results of La Marca et al. [18] might
be explained by the lack of detailed longitudinal data asused in the study presented here. Furthermore, we ob-
served a significant increase in AMH levels on day 4
postpartum, whereas in the study of La Marca blood
samples were taken only on days 2 and 3 postpartum.
As our study suggests, the ovary seems to be
suppressed in pregnancy and relegated to a nearly pre-
pubertal quiescent state. In prepubertal state, there are
low AMH values despite a high ovarian reserve [21].
AMH production recovered after delivery, showing a
small but significant increase by the fourth day postpar-
tum, suggesting an immediate recovery of follicular de-
velopment after delivery.
Our data are consistent with a study by Weghofer
et al. [22] who investigated AMH levels in a cohort of
210 women without evidence of impaired fertility 14
days after delivery in order to determine an age-related
difference. Across three different age groups (18–30
years, 30–36 years and 37–40 years; 70 patients each),
AMH levels fourteen days after delivery were much
lower than among infertile women. The authors con-
cluded that the hormonal suppression of pregnancy led
to a reduction in AMH levels which did not correlate
with the size of the pool of follicles, but with ovarian
function.
Weghofer et al. [22] examined the women only once
after delivery, whereas in our study we also examined
pregnant women. Going beyond Weghofer et al. [22] we
were able to describe an AMH increase within a few
days after delivery.
Our study results offer biological plausibility. Follicu-
logenesis in pregnancy seems to be inhibited, so that
even the most primordial follicles seem to be in a resting
state and AMH is no longer produced. The loss of the
hormone producing placenta could be the cause for an-
other drop in AMH levels after delivery and before a
subsequent rise. Thus, in addition to the hormones pro-
gesterone and estrogen, other placental factors may
amplify the strong ovarian suppression and could ex-
plain the further drop of AMH after delivery. One ex-
planation might be that FSH is strongly suppressed in
pregnancy as well as in the first three days after delivery
[18]. We looked for a possible candidate which could be
responsible for this FSH suppression peripartal. Beyond
the sexual steroids, the activin-binding protein Follistatin
suppresses FSH synthesis and secretion. As shown by
Rae et al. [23] Follistatin increases during pregnancy and
is still enhanced during the first day after delivery,
returning to values similar to those in late pregnancy at
the second day after birth. Because of the short half-time
of Follistatin, the authors concluded that the placenta
may not be the only source of Follistatin. Other authors
assume a role in tissue repair by Follistatin to explain
the short-term postpartal increase [24]. In the context of
our study results, Follistatin may contribute to further
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needed to examine a potential interaction of Follistatin
or other possible candidates for FSH suppression, Anti-
Mullerian- Hormone and ovarian suppression during
pregnancy.
From our perspective, ovarian suppression may func-
tion as fertility preserving. Our results give support to
the hypothesis of ovarial protection in full term preg-
nancy, using AMH as a serum marker. This is in accor-
dance with the observation that women reaching
full-term pregnancies get postmenopausal significantly
later in their lifetime compared to nulliparous women.
This has been reported in a variety of epidemiological
studies from different ethnicities [25-32].
Limitations
Despite several strengths, our study is limited by the fact
that we were not able to measure AMH levels during
pregnancy and peripartal in all patients to obtain longi-
tudinal data at different stages in pregnancy and beyond
for the whole study population. Therefore, our results
have to be confirmed in a prospective population-based
pregnancy cohort with detailed information on AMH
levels during pregnancy as well as during the first days
postpartum.
Conclusions
AMH levels decline during pregnancy. Our study shows
that AMH cannot be accepted as a parameter of ovarian
reserve that remains unchanged irrespective of the hor-
monal circumstances of women, e.g. pregnancy. Further-
more, a full-term pregnancy may lead to suppression of
the ovary as shown by a significant decrease in AMH
levels during pregnancy and the quick increase postpar-
tum. This may lead to misinterpretation of the actual
ovarian reserve in pregnancy and postpartum.
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